secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-06-25T23:59:59+00:00
Accession:  0001193125-24-167481
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated
--------------------------------------------------------------------------------

- SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).
- Wild-type HTT preserved; allele-selective silencing confirmed.
- mHTT reduction correlated with slowing of caudate atrophy (R=-0.50, p=0.047), an imaging biomarker predictive of clinical outcomes.
- Generally safe and well-tolerated; no serious adverse events reported.
- Cash runway into Q4 2025; Wave to discuss accelerated approval path with regulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524167481/0001193125-24-167481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524167481/d771392d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-167481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer